|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases:a predictive index of liver histology severity显示文摘UltrasounddetectionofabdominallymphadenomegalyinsubjectswithhepatitisCvirusinfectionandpersistentlynormaltransaminases:apredi... | Maurizio Soresi, Antonio Carroccio, Giulio Bonfissuto, Vincenzo Agate 1, Carmela Magliarisi, Federico Aragona 1, Massimo Levrero 2, Alberto Notarbartolo and Giuseppe Montalto Cattedra di Medicina Interna, 1Istituto di Anatomia Patologica, Univ | 1998 | World Journal of Gastroenterology1998，4，3： | 15 |
| 2 | Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients显示文摘The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant.However,despite the long use of tacrolimus in clinical practice,the best way to use this agent is still a matter of intense debate.The start of the genomic era has generated new research areas,such as pharmacogenetics,which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body.This variability seems to be correlated with the presence of genetic polymorphisms.Genotyping is an attractive option especially for the initiation of the dosing of tacrolimus;also,unlike phenotypic tests,the genotype is a stable characteristic that needs to be determined only once for any given gene.However,prospective clinical studies must show that genotype determination before transplantation allows for better use of a given drug and improves the safety and clinical efficacy of that medication.At present,research has been able to reliably show that the CYP3A5 genotype,but not the CYP3A4 or ABCB1 ones,can modify the pharmacokinetics of tacrolimus.However,it has not been possible to incontrovertibly show that the corresponding changes in the pharmacokinetic profile are linked with different patient outcomes regarding tacrolimus efficacy and toxicity.For these reasons,pharmacogenetics and individualized medicine remain a fascinating area for further study and may ultimately become the face of future medical practice and drug dosing. | Alessio Provenzani Andrew Santeusanio Erin Mathis Monica Notarbartolo Manuela Labbozzetta Paola Poma Ambra Provenzani Carlo Polidori Giovanni Vizzini Piera Polidori Natale D'Alessandro | 2013 | World Journal of Gastroenterology2013，19，48： | 15 |
| 3 | Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population显示文摘 | D. Noto A.B. Cefalù C.M. Barbagallo M. Sapienza G. Cavera I. Nardi M. Pagano N. Vivona A. Notarbartolo M.R. Averna | 2008 | Nutrition Metabolism and Cardiovascular Diseases2008，，5： | 1 |
| 4 | Curcumin as a possi- ble lead compound against hormone-independent multidrug-resistant breast cancer显示文摘 | Labbozzetta M Notarbartolo M Poma P | 2009 | Ann N Y Acad Sci2009，1155，： | 1 |
| 5 | Effect of ezetmibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: aprospective, randomized, double-blind trial显示文摘 | Ballantyne CM Houri J Notarbartolo A | 2003 | Circulation2003，107，19： | 1 |
| 6 | Resistance to di-verse apoptotic triggers in multi-drug resistant HL-60 cells andits possible relationship to the expression of P-glycoprotein,Fasand of the novel anti-apoptosis factors IAP显示文摘 | Notarbartolo M Cervello M Dusonehet L | 2003 | Cancer Lett2003，180，： | 1 |
| 7 | Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression显示文摘 | Notarbartolo M Poma P Perri D | 2005 | Cancer Lett2005，224，1： | 1 |
| 8 | Resistance to diverse apoptotic triggers in multidrug resistant HL60 ceils and its possible relationship to the expression of P-glycoprotein, Fas and of the novel antiapoptosis factors IAP ( inhibitory of apoptosis proteins ) 显示文摘 | Notarbartolo M Cervello M Dusonchet L | 2002 | Cancer Lett2002，180，1： | 1 |
| 9 | Anti-tumor ef- fects of the novel NF-KB inhibitor dehydroxyme-thyl-e- poxyquinomicin on human hepatic cancer cells: Analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production 显示文摘 | Poma P Notarbartolo M Labboz M | 2006 | Int J Onco12006，28，4： | 1 |
| 10 | Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hype-rcholesterolemia: a prospective, randomized, double-blind trial 显示文摘 | BALLANTYNE C M HOURI J NOTARBARTOLO A | 2003 | Circulation2003，107，： | 1 |
| 11 | Effect of ezetimibe coadminis-tered with atorvastatin in628patients with primary hypercholesterolemia:a prospective,randomized,double-blind trial显示文摘 | Ballantyne CM Houri J Notarbartolo A | 2003 | Circulation2003，107，： | 1 |
| 12 | Effect of Ezetimibe eoadministered with Atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double- blind trial显示文摘 | Ballantyne CM Houri J Notarbartolo A | 2003 | Circulation2003，107，19： | 1 |
| 13 | Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia显示文摘 | Davi G Avena M | 1995 | Arterioscler Thromb Vasc Bioi1995，15，： | 1 |
| 14 | The effect of CYP3A4 and ABCB1 single nu-cleotide polymorphisms on tacrolimus dose requirements inCaucasian liver transplant patients 显示文摘 | Alessio Provenzani Monica Notarbartolo Manuela Lab-bozzetta | 2009 | Ann Transplant2009，14，1： | 1 |
| 15 | Effect of ezetimibe coadministration with atorvastatin in 628 patients with primary hypercholesterolenia: a prospective, randomized, double-blind trial 显示文摘 | Ballantyne CM Houri J Notarbartolo A | 2003 | Circulation2003，107，19： | 1 |
| 16 | Expressionof the IAPs in multidrug resistant tumor cells显示文摘 | Notarbartolo M Cervello M Poma P | 2004 | Oncol Rep2004，11，1： | 1 |
| 17 | Induction of apoptosis by the proteasome inhibitor MGI32 in human HCC cells:Porssible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-calenin-mediated transactivation显示文摘 | Cervello M Giannitrapani L La Rosa M Notarbartolo M Labbozzetta M Poma P | 2004 | Int J Mol Med2004，13，74： | 1 |
| 18 | Inhibition of thromboxanebiosynthesis and platelet function by simvastatin in type IIahypercholesterolemia显示文摘 | Notarbartolo A Davi G Averna M | 1995 | Arterioscler Thromb Vasc Biol1995，15，2： | 1 |
| 19 | Influence of CYP3A5 and ABCBI gene polymorpbisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients 显示文摘 | Provenzani A Notarbartolo M Labbozzetta M | 2011 | lnt J Mol Med2011，28，6： | 1 |
| 20 | Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-lycoprotein, Fas and of the novel anti-apoptosis factors IAP 显示文摘 | Notarbartolo M Cervello M Dusonchet L | 2002 | Cancer Lett2002，180，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员